Revenue Analysis – Global Pancreatic Cancer Market Till 2021

1
Frontier Pharma Pancreatic Cancer- Identifying
and Commercializing First- in- Class Innovation
Published on 01 June, 2015 Number of pages
88 Single User Price 6995
Pancreatic cancer is the 12th most common cancer
globally, and the fourth most fatal, with a
mortality rate of 10.9 deaths per 100,000 people
per year. The poor prognosis of pancreatic cancer
patients has highlighted a significant need for
new and improved approaches to treatment, which
is not being met by the current market.
2
Summary of the ReportPancreatic cancer is the
12th most common cancer globally, and the fourth
most fatal, with a mortality rate of 10.9 deaths
per 100,000 people per year. The poor prognosis
of pancreatic cancer patients has highlighted a
significant need for new and improved approaches
to treatment, which is not being met by the
current market. A highly active pancreatic
cancer pipeline contains an array of products
with varying molecule types and mechanisms of
action, which provides a striking contrast to the
current, chemotherapy dominated, market. Within
the pipeline, there are 185 products that act on
a first-in-class molecular target, representing
52 of the total pancreatic cancer pipeline
products that have a disclosed molecular target.
A drastically different pipeline and market
composition implies that the approach to
pancreatic cancer treatment is changing and
first-in-class innovation is playing a
significant role in this.
Click Here To Check Complete Report
3

• Scope of the Report
• Gemcitabine based regimens continue to dominate
  the market, which has seen few new entrants over
  the past decade. The continued reliance on
  generic chemotherapies is one reason why the
  prognosis has shown little improvement.
• What survival benefits do current therapies
  provide?
• What are the current unmet needs that the
  pipeline needs to address?
• The pipeline contains a plethora of molecule
  types and molecular targets not present on the
  market, including a large focus on therapies
  targeting common oncogenic pathways and signaling
  intermediates such as PI3K/Akt.
• What impact will the emergence of biologics have
  on the pancreatic cancer landscape?
• Will pipeline diversity translate to clinically
  and commercially successful therapies?
• How will the rise of novel molecular target
  categories, such as signal transduction, impact
  future treatment options?
• 52 of pipeline products act on a first-in-class
  target, which is higher than the oncology and
  industry averages.
• Do first-in-class products show strong
  progression into the later stages?
• Why is the greatest number of first-in-class
  products seen in signal transduction?

Download Sample Brochure
4

• Reasons to buy
• This report will allow you to -
• Understand the current clinical and commercial
  landscape. This includes a comprehensive study of
  disease pathogenesis, diagnosis, prognosis and
  the available treatment options available at each
  stage of diagnosis.
• Visualize the composition of the pancreatic
  cancer market in terms of dominant molecule types
  and targets, highlighting what the current unmet
  needs are and how they can be addressed. This
  knowledge allows a competitive understanding of
  gaps in the current market.
• Analyze the pancreatic cancer pipeline, and
  stratify by stage of development, molecule type
  and molecular target. There are promising signs
  in the pipeline that the industry is seeking
  novel approaches the treating pancreatic cancer.
• Assess the therapeutic potential of
  first-in-class targets. Using a proprietary
  matrix, first-in-class products have been
  assessed and ranked according to clinical
  potential.Promising targets, including MAP3K7 and
  P70-S6 Kinase 1 have been extensively reviewed
  using peer-reviewed literature and preclinical
  data.

Make an Inquiry Before Buying
5
Frontier Pharma Pancreatic Cancer- Identifying
and Commercializing First- in- Class Innovation
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Pancreatic Cancer Market are provided in the
report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Pancreatic Cancer
Market Report